Related Experiment Videos
Introduction: treatment of malignancies poorly responsive to currently available antineoplastic therapy
1Cleveland Clinic Cancer Center, OH 44195.
Abstract:
The decision whether to treat patients with malignancies that are poorly responsive to antineoplastic agents must be based on a number of important considerations, including the patients' performance status, co-morbid medical conditions, and the anticipated adverse effects of therapy. In appropriate patients, participation in experimental trials should be encouraged. In such circumstances, patients and their families must be given a realistic assessment of the limited or unknown benefits of treatment.
Insights
Treating malignancies resistant to chemotherapy requires careful patient assessment, including performance status and co-morbidities. Experimental trials may be suitable for select patients, with transparent communication about potential benefits and risks.
Area of Science:
- Oncology
- Clinical Decision-Making
- Cancer Therapeutics
Background:
- Malignancies often exhibit poor responsiveness to standard antineoplastic agents.
- Treatment decisions for refractory cancers are complex and multifactorial.
Purpose of the Study:
- To outline key considerations for treating patients with malignancies poorly responsive to antineoplastic agents.
- To emphasize the role of experimental trials and informed consent in managing refractory cancers.
Main Methods:
- Review of clinical decision-making principles for refractory malignancies.
- Discussion of patient-specific factors influencing treatment choices.
- Emphasis on ethical considerations in experimental therapeutics.
Main Results:
- Treatment decisions necessitate evaluation of patient performance status, co-morbidities, and anticipated adverse effects.
- Experimental trials offer an option for appropriate patients with refractory cancers.
- Realistic assessment of treatment benefits is crucial for informed consent.
Conclusions:
- Individualized patient assessment is paramount when considering treatment for refractory malignancies.
- Experimental trials should be encouraged for suitable candidates, ensuring transparent communication.
- Balancing potential benefits against risks is essential for patient-centered care in oncology.